Executive Summary
CapRegen plc is a newly incorporated public limited company that has been established in order to make investments in the global anti-ageing and regenerative medicine market place. The Company will use the expertise of the Executive Directors to invest in medical technologies that they and the other Directors believe have commercial viability. The Company will seek to invest in technologies and products in the anti-ageing healthcare marketplace. The Company intends to: * fund scientific researchers with early-concept technologies with short term commercial viability. Typically, investments in non-FDA regulated technologies will tend to be 1-3 years from commercialisation and investments in FDA regulated technologies will tend to be 5-7 years from market; and * generate early intelligence of new technologies under development in university laboratories. Any such investment is likely to be unquoted and located, at least initially, primarily in North America, although the Directors may look to make investments around the world if appropriate. It is anticipated that the Company will make several investments rather than focussing on just one or two.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
